NCT05980052 Goal Setting to Promote Physical Activity Adherence in Midlife Adults
| NCT ID | NCT05980052 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Arizona State University |
| Condition | Physical Activity |
| Study Type | INTERVENTIONAL |
| Enrollment | 144 participants |
| Start Date | 2023-07-17 |
| Primary Completion | 2027-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 144 participants in total. It began in 2023-07-17 with a primary completion date of 2027-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Engaging in regular physical activity during midlife is a key lifestyle behavior associated with reduced risk for Alzheimer's disease and related dementias (AD/ADRD). Yet nearly half of midlife adults (48%) do not meet national physical activity guidelines. The purpose of this mechanistic trial is to identify effective goal setting techniques to enhance psychosocial processes of self-regulation for the successful promotion of PA and adherence to national PA guidelines among midlife adults, with the long-term goal of reducing AD/ADRD risk
Eligibility Criteria
Inclusion Criteria: * Aged 45 to 65 years * BMI between 30 kg/m2 to 50 kg/m2 * Participants must weigh a minimum of 110 pounds * Engaging in 60 minutes or less of self-reported moderate-to-vigorous physical activity at screening (based on Exercise Vital Sign Questionnaire) * Self-reported ownership of a smartphone with an iOS or Android operating system (necessary for participants to track their activity using a Fitbit activity monitor) Exclusion Criteria: * Endorsing an item on the Physical Activity Readiness Questionnaire (PAR-Q), unless a physician's note is provided * Resting blood pressure greater than 200/110 mmHG as assessed at the baseline study assessment (unless a physician's note is provided) * Pregnant or planning to become pregnant in next 8-months (Phase 1) or 12 months (Phase 2) * Plans to relocate out of metropolitan Phoenix, Arizona area in the next 8-months (Phase 1) or 12 months (Phase 2) * Participation in another physical activity, nutrition or weight loss program at time of screening or at any time during the intervention * Individuals with mild cognitive impairment (MCI), as determined by either a self-report of receiving a diagnosis of MCI from a health care provider or as assessed by the Montreal Cognitive Assessment (MoCA) at the study orientation session. A score \< 26 is an exclusion criterion for US born participants. A score of \<23 is an exclusion for participants born outside of the US who completed their high school education in a country where English is not the primary language. * Being previously prescribed one of the 5 approved Alzheimer's medications, including: Donepezil (Aricept), Rivastigmine (Exelon), Galantamine (Razadyne), Memantine (Namenda), Memantine + Donepezil (Namzaric) * Score of 16 or higher on the Center for Epidemiological Studies-Depression Scale (CES-D) * Self-reported current diagnosis of major depression * Currently taking 2 or more ant-depression drugs * History of stroke * Incarcerated individuals (i.e., Prisoners)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05980052 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, up to 65 Years, studying Physical Activity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05980052 currently recruiting?
Yes, NCT05980052 is actively recruiting participants. Contact the research team at rodney.joseph@asu.edu for enrollment information.
Where is the NCT05980052 trial being conducted?
This trial is being conducted at Phoenix, United States.
Who is sponsoring the NCT05980052 clinical trial?
NCT05980052 is sponsored by Arizona State University. The trial plans to enroll 144 participants.